Transformative Research in Diabetic Nephropathy

Launched by UNIVERSITY OF PENNSYLVANIA · Dec 7, 2016

Keywords

ClinConnect Summary

This clinical trial, called "Transformative Research in Diabetic Nephropathy," is studying how diabetes affects kidney health. Researchers are looking at patients with diabetes who need a kidney biopsy, which is a procedure where a small sample of kidney tissue is taken for testing. The goal is to understand the differences between patients who experience a rapid decline in kidney function and those who have a slower change. By analyzing kidney tissue, blood, urine, and genetic information, the researchers hope to find new ways to treat diabetic kidney disease.

To participate in this study, you must be an adult with either Type 1 or Type 2 diabetes, and you should be scheduled for a kidney biopsy as recommended by your doctor. You also need to be willing to follow the study's requirements, including attending follow-up visits. However, if you have end-stage kidney disease, a history of certain cancers, or other specific health issues, you may not be eligible. Participants can expect to undergo the biopsy and provide samples for analysis, which will help researchers identify potential new treatments for diabetic kidney problems.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Type 1 and 2 Diabetes by American Diabetes Association (ADA) criteria
• • Willingness to comply with study requirements, including intention to fully participate in protocol-specified follow-up at a clinical study site
• • Able to provide informed consent
• • Adult participants
• • Planned medically indicated kidney biopsy, prescribed by a practicing nephrologist
• Exclusion Criteria:
• • End Stage Renal Disease (ESRD), defined as chronic dialysis or kidney transplant
• • History of receiving dialysis for more than 30 days prior to biopsy
• • Institutionalized
• • Solid organ or bone marrow transplant recipient at time of first kidney biopsy
• • Less than 3-year life expectancy
• • History of active alcohol and/or substance abuse that in the investigator's assessment would impair the subject's ability to comply with the protocol
• • Unable to provide informed consent
• • Evidence of active cancer requiring treatment, other than non-melanoma skin cancer